Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: avadel.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $12.00 | Buy | Deutsche Bank |
| 6/12/2024 | $27.00 | Buy | Rodman & Renshaw |
| 3/5/2024 | $27.00 → $29.00 | Outperform | Oppenheimer |
| 3/5/2024 | $21.00 → $25.00 | Buy | H.C. Wainwright |
| 3/5/2024 | $20.00 → $22.00 | Buy | Needham |
| 2/6/2024 | $21.00 | Buy | UBS |
| 11/30/2022 | $6.50 → $11.00 | Hold → Buy | Jefferies |
| 8/10/2022 | $6.00 → $8.00 | Buy → Hold | Jefferies |
| 7/28/2022 | $15.50 → $12.00 | Buy | Craig Hallum |
| 5/26/2022 | $9.00 → $2.00 | Buy → Hold | Stifel |
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the se
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the "Delaware Court") rega
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- DUBLIN, April 17, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and nference, a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data on comorbidities and treatm
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company provided an update on patient demand metrics that was in line with guidance from its full-year results announcement on March 3, 2025. It also addressed questions related to the recent developments in United States tariff policy and the potential impact on the biopharmaceutical sector, including Avadel. Specifically: In Q1 2025 patient demand metrics for LUMRYZ™, Avadel's innovative narcolepsy medication with a market potential of a
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach in
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled "A New Dawn in the Management of Narcolepsy". "I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular emphasis on sodium oxybate therapy, an underutilized treatment option," said Michael J. Thorpy,
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following each conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (NASD
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
10-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously
H.C. Wainwright reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $21.00 previously
Needham reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $20.00 previously
UBS initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $21.00
Jefferies upgraded Avadel Pharmaceuticals from Hold to Buy and set a new price target of $11.00 from $6.50 previously
Jefferies downgraded Avadel Pharmaceuticals from Buy to Hold and set a new price target of $8.00 from $6.00 previously
Craig Hallum resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00 from $15.50 previously
Stifel downgraded Avadel Pharmaceuticals from Buy to Hold and set a new price target of $2.00 from $9.00 previously
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. "We are pleased to welcome Brandi to the Avadel team as our Senior Vice President, Corporate Affairs as we continue to advance once-at-bedtime FT218 for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy," said Greg Divis, Chief Executive Officer of Avadel. "Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the compa
DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer. "Doug is an outstanding addition to the Avadel leadership team given his extensive experience in the biopharmaceutical industry leading R&D, clinical development and medical affairs teams in the neuroscience field," said Greg Divis, Chief Executive Officer of Avadel. "His expertise in pre- and post-approval clinical development, data generation and regulatory strategy will support all aspects of FT218 as we look to bring this important treatment t
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs, effective immediately. In this role her responsibilities will include overseeing all medical and clinical affairs activities, including the company’s lead program, once-nightly FT218. “We are pleased to further strengthen our team with the appointment of Dr. Gudeman. Her broad med
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here a
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of $240 – $260 million in 2025, representing 50% year-over-year growth at the midpoint -- -- Management to host a conference call today at 4:30 p.m. ET -- DUBLIN, Ireland, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a busines
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and anno
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and use the conference ID 2270373. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023. Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on Thursday, February 29. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the web